Comment on 'Cost effectiveness of collagen crosslinking for progressive keratoconus in the UK NHS'.
Department of Ophthalmology, Utrecht Cornea Research Group, University Medical Centre Utrecht, Utrecht, The Netherlands.
D A
DA
Godefrooij
Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands.|National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
G A
GA
de Wit
Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands.
M J
MJ
Mangen
Department of Ophthalmology, Utrecht Cornea Research Group, University Medical Centre Utrecht, Utrecht, The Netherlands.
R P L
RP
Wisse
D003094:Collagen / Q000627:therapeutic use; D003319:Corneal Stroma; D003362:Cost-Benefit Analysis; D003432:Cross-Linking Reagents / Q000627:therapeutic use; D006801:Humans; D007640:Keratoconus / Q000188:drug therapy*; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D012256:Riboflavin / Q000627:therapeutic use; D014466:Ultraviolet Rays; D014792:Visual Acuity
D003432:Cross-Linking Reagents; D017319:Photosensitizing Agents; D003094:Collagen; D012256:Riboflavin